Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil added to Epoprostenol in PAH (PACES)
NCT00159861Phase 3Completed
- Sponsor
- Viatris
- Start
- Jul 2003
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Sildenafil + Epoprostenol with Placebo + Epoprostenol (2 arms). Primary endpoint: 6-Minute Walking Distance at 3 years. Started Jul 2003; status: completed.
02
Drugs
sildenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00159861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00159861.